Tianjin Tianyao Pharmaceuticals (SHA:600488) secured registration approval for formoterol fumarate active pharmaceutical ingredient (API) from China's drug administrator.
Formoterol fumarate is used to treat chronic obstructive pulmonary disease, chronic bronchitis, and emphysema, according to a Monday filing with the Shanghai bourse.
Shares of the company closed 2% higher Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.